---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000013"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:14:59.413947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics FY2024 net loss $18.5M; clinical hold lifted, Phase 3 CATT1 to resume Q2 2025

## Summary
- Clinical hold on cadisegliatin program lifted March 14, 2025; Phase 3 CATT1 T1D trial to resume Q2 2025 with protocol amendment shortening to 6 months.
- FY2024 net loss attributable to shareholders $18.5M ($3.20/share) vs $20.3M ($9.71/share) in FY2023.
- Cash $36.7M at Dec 31, 2024, up from $9.4M a year earlier, boosted by private placement and ATM offering.
- Appointed Martin Lafontaine as Chief Commercial Officer; he brings over 25 years of diabetes commercial experience.
- R&D expenses fell to $11.5M in FY2024 from $13.6M in FY2023, due to reduced cadisegliatin costs.

## SEC filing metadata
- accession: 0001641489-25-000013
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/0001641489-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000013/vtvt-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000013
- JSON: https://secwatch.observer/filing/0001641489-25-000013.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.